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Abstract

Traceable poly(ethylene oxide)-poly(ester) micelles were developed through chemical

RI
PT

conjugation of a near-infrared (NIR) dye to the poly(ester) end by click chemistry. This strategy
was tried for micelles with poly(ε-caprolactone) (PCL) or poly(α-benzyl carboxylate-εcaprolactone) (PBCL) cores. The surface of both micelles was also modified with the breast

SC

cancer targeting peptide, P18-4. The results showed the positive contribution of PBCL over PCL
core on micellar thermodynamic and kinetic stability as well as accumulation in primary

M
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orthotopic MDA-MB-231 tumors within 4-96 h following intravenous administration in mice.
This was in contrast to in vitro studies where better uptake of PEO-PCL versus PEO-PBCL
micelles by MDA-MB-231 cells was observed. The presence of P18-4 enhanced the in vitro cell
uptake and homing of both polymeric micelles in breast tumors, but only at early time points. In

TE
D

conclusion, the use of developed NIR labeling technique provided means for following the fate
of PEO-poly(ester) based nano-carriers in live animals. Our results showed micellar stabilization
through the use of PBCL over PCL cores, to have a more significant effect in enhancing the level

EP

and duration of nano-carrier accumulation in primary breast tumors than the modification of

AC
C

polymeric micellar surface with breast tumor targeting peptide, P18-4 peptide.

Keywords: Breast cancer, nanocarriers, living imaging, polymeric micelles, biodistribution.
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1. Introduction

Proper design and development of nanocarriers capable of tumor accumulation and

RI
PT

targeted drug delivery has been the focus of several studies in recent years. The common practice
is to modify the chemical structure of biomaterial building blocks, in order to optimize the size,
morphology and stability of self-assembled nanostructures for passive accumulation into solid

SC

tumors through enhanced permeation and retention (EPR) effect [1–3]. Surface modification
with targeting ligands can also be pursued to enhance the homing and interaction of

M
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nanoparticles with tumor cells. Success of the latter approach would depend on finding the
appropriate ligand at the optimum ligand surface density [4,5]. Development of traceable
nanocarriers, which can be visualized in live animals, can expedite their optimization process for
enhanced drug delivery to tumor cells. Traceable nanocarriers can also be further developed for
use in the personalization of cancer therapy, detection of cancer progress and/or monitoring of

TE
D

treatment outcome in patients [6,7].

The objective of this study was to, first, develop traceable poly(ethylene oxide)-poly(ε-

EP

caprolactone) (PEO-PCL) based polymeric micelles; then use this technology to investigate the
effect of adding a hydrophobic pendent group (i.e. aromatic, benzyl group) on the PCL block as

AC
C

well as a surface peptide ligand on the in vivo biodistribution of the corresponding nanocarriers
in a breast tumor-bearing animal model.
Self-assembled nanostructures composed of poly(ethylene oxide)-poly(ester)s such as

PEO-PCL [8–11], poly(ethylene oxide)-poly(lactide) (PEO-PLA) [12,13], and poly(ethylene
oxide)-poly(lactide-co-glycolide) (PEO-PLGA) [14,15] have been the subject of tremendous
research for drug solubilization and targeted delivery in cancer [16]. The increasing interest in
the use of these structures is due to their biocompatibility, biodegradability and safe history of
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use in human [17,18]. However, despite a long history of use as drug delivery systems, limited
information on the effect of structural features affecting core hydrophobicity and thus micellar
stability among nanocarriers formed from poly(ethylene oxide)-poly(ester)s on their

RI
PT

biodistribution and in vivo tumor targeting is available [5,19–21]. Previously, we have reported
on the development of novel self-associating PEO-poly(ester) based block copolymers through
introduction of pendant benzyl carboxylate groups to the PCL segment of PEO-PCL leading to

SC

the production of PEO-poly(α-benzyl carboxylate-ε-caprolactone) (PEO-PBCL) [22]. This
modification, according to our in vitro studies, increases the kinetic and thermodynamic stability,

M
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and also decreases the rate of degradation of polymeric micelles formed through self-association
of these block copolymers [23]. In the current study, traceable nanocarriers based on PEO-PCL
and PEO-PBCL were developed through chemical conjugation of a near infrared dye (NIR) to
their core-forming block for live imaging of mice bearing tumors. The NIR labeling provided

TE
D

means to assess the effect of core structure on the extent and kinetics of primary tumor
accumulation, for plain nanocarriers as well as those surface-modified with a novel breast tumor

EP

targeting peptide, P18-4, in an orthotopic breast cancer mouse model.

AC
C

2. Materials and methods

2.1.Materials

Methoxy-polyethylene oxide (PEO) (average molecular weight of 5000 g/mol) and

cholera toxin were purchased from Sigma (St. Louis, MO). ε-Caprolactone was purchased from
Lancaster Synthesis (UK). α-Benzyl carboxylate-ε-caprolactone monomer was synthesized by
Alberta Research Chemicals Inc (Edmonton, AB) according to a previously published procedure
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[22]. α-Propargyl carboxylate-ε-caprolactone (PCC) monomer was synthesized according to a
previously published procedure [24]. Stannous octoate was purchased from MP Biomedicals Inc.
(Germany). Cy5.5-azide was purchased from Lumiprobe (Hallandale Beach, FL). Cell culture

RI
PT

media MEM, fetal bovine serum (FBS), sodium pyruvate, L-glutamine, non-essential amino
acids, and penicillin-streptomycin-fungizone (Anti-Anti) were purchased from GIBCO, Life
Technologies Inc. (Burlington, ON, Canada). MEGM medium kit was purchased from Lonza

SC

(Basel, Switzerland). Peptide P18-4 was synthesized according to a previously published
procedure [25]. 2014S Teklad Global 14% protein rodent maintenance diet was purchased from

M
AN
U

Harlan Labs (Indianapolis, IN). Spectra/por dialysis tubing (MWCO - 3.5 kDa) was purchased
from Spectrum Laboratories (Rancho Dominguez, CA). Dry toluene was prepared by refluxing
under H2SO4. All other chemicals were reagent grade.

TE
D

2.2. Cell lines

The luciferase expressing human breast cancer cell line MDA-MB-231 (clone D3H2LN)
was purchased from Caliper Life Sciences (Woodbridge, ON, Canada). The MDA-MB-231-luc-

EP

D3H2LN cells were grown in MEM medium supplemented with 10% FBS, 1mM sodium
pyruvate, 0.1 mM non-essential amino acids (NEAA), 2 mM L-glutamine, 100 IU/mL penicillin,

AC
C

100 µg/mL streptomycin, and 0.25 µg/mL fungizone at 37 °C in 5% CO2 atmosphere. The
human mammary cell line MCF10A was purchased from ATCC (Manassas, VA). The MCF10A
cells were grown in MEGM medium kit supplemented with 100 ng/mL cholera toxin at 37 °C in
5% CO2 atmosphere.

2.3. Synthesis of Cy5.5 conjugated block copolymers

5
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Block copolymers of PEO-PCL and PEO-PBCL were synthesized by ring-opening
polymerization of ε-caprolactone (0.1 g) or α-benzyl carboxylate-ε-caprolactone (0.2 g),

catalyst according to a method described previously [8,22,26].

RI
PT

respectively, using methoxy-PEO (MW: 5000 g/mol) (0.5 g) as initiator and stannous octoate as

Block copolymers of PEO-PCL or PEO-PBCL were end capped with α-propargyl
carboxylate-ε-caprolactone (PCC) using stannous octoate as catalyst. Briefly, PEO-PCL (0.1 g)

SC

and PCC (0.014 g) or, PEO-PBCL (0.1 g) and PCC (0.012 g) were added to a 25 mL round-
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bottom flask previously filled with 5 mL dry toluene under constant stirring. Stannous octoate
(0.010 equiv of monomer) was added to the flask. The flask was then refluxed for 30 h. The
reaction was terminated by cooling the product to room temperature. The product was then
precipitated in hexane and the supernatant was discarded. The final product was washed with
ether and dried under vacuum for further use.

TE
D

Near-infrared fluorophore (NIRF) Cy5.5-azide was conjugated to the terminal alkyne of
PCC in PEO-PCL-PCC or PEO-PBCL-PCC using Huisgens 1,3-dipolar cycloaddition (azidealkyne click chemistry) reaction. The terminal alkyne group of PCC reacted with the terminal

EP

azide group of Cy5.5 azide to form a 1,3-triazole ring. Cu(I) acts as a catalyst for the reaction.
Cu(I) is prepared in situ by the addition of Cu(II) TBTA Complex, and ascorbic acid, reducing

AC
C

Cu(II) to Cu(I). Briefly, 10 µmol PEO-PCL-PCC (68 mg) or PEO-PBCL-PCC (75 mg) was
dissolved under constant stirring in a 10 mL round-bottom flask containing 2 mL degassed
DMSO. Cy5.5 azide (1 µmol; 0.7 mg) was dissolved in 400 µL DMSO and added to the mixture
under constant stirring followed by addition of ascorbic acid (0.5 µmol; 0.1 mg) previously
dissolved in 100 µL water. The flask was then degassed with argon for about 30 s. 10 mM CuTBTA Complex solution (0.5 µmol; 60 µL) was finally added followed by degassing for 30 s
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using argon. The reaction mixture was sealed and incubated with stirring at room temperature in
the dark for 16 h. Argon was flushed through the sealed vial at 4 and 8 h time-points. After
incubation, the mixture was separated from the non-reacted dye by dialysis against DMSO for 24

2.4. Synthesis of P18-4 modified block copolymers

RI
PT

h followed by dialysis against water for 24 h to remove the DMSO, and then lyophilized.

SC

Acetal-PEO-PCL and acetal-PEO-PBCL were synthesized according to a previously
published procedure [27]. P18-4-attached PEO-PCL or PEO-PBCL were synthesized from

M
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acetal-PEO-PCL or acetal-PEO-PBCL according to a previously published procedure [5,28].
Briefly, acetal-PEO-PCL and acetal-PEO-PBCL block copolymer micelles were prepared
through formation of micelles (6 mg/mL) by a co-solvent evaporation method as described
previously [8,22]. The micellar solution was then acidified to pH 2 with 0.5 M HCl and stirred

TE
D

for 2 h at room temperature. The resulting solution was then neutralized with 0.5 M NaOH to pH
7 followed by addition of an appropriate volume of concentrated PBS to maintain the pH at 7.4.
An aqueous solution of the peptide P18-4 in 1% DMSO was prepared and was added to the

EP

micellar solution under constant stirring such that the P18-4:polymer molar ratio is 1:5. The
solution was allowed to stir for 2 h after which NaBH3CN (10 eq.) was added and the reaction

AC
C

was stirred for 96 h. The resulting micellar solution was dialyzed against distilled water and
lyophilized.

2.5. Characterization of synthesized block copolymers
The number-average molecular weight of PEO-PCL and PEO-PBCL block copolymers
was determined from the 1H NMR spectrum of the block copolymers in CDCl3 (600 MHz,
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Bruker Avance III instrument, Bruker BioSpin Corporation, Billerica, MA) by comparing the
peak intensity of methylene hydrogens of PEO (-CH2CH2O-, δ = 3.65 ppm) to the hydrogens of
methylene group of PCL or PBCL backbone (-OCH2-, δ = 4.05 ppm), considering a 5000 g/mol

RI
PT

molecular weight for PEO.

The number-average molecular weight of PEO-PCL-PCC and PEO-PBCL-PCC tri-block
copolymers was determined from the 1H NMR spectrum of the block copolymers in CDCl3 at

SC

600 MHz by comparing the peak intensity of the hydrogens of PEO (-CH2CH2O-, δ = 3.65 ppm)
to the methylene hydrogens of PCC block (-OCH2-, δ = 4.75 ppm), considering a 5000 g/mol

M
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U

molecular weight for PEO.

The conjugation efficiency of Cy5.5 to PEO-PCL-PCC and PEO-PBCL-PCC was
determined by fluorescence spectrophotometer using a SpectraMax M4 microplate reader
(Molecular Devices, Sunnyvale, CA), measuring the excitation at 673 nm and emission at 707

TE
D

nm as described the manufacturer. The conjugation efficiency of P18-4 peptide to acetal-PEOPCL and acetal-PEO-PBCL micelles was determined by reverse-phase HPLC according to a

EP

previously published procedure [5,28].

2.6. Preparation and characterization of block copolymer micelles

AC
C

Cy5.5-loaded PEO-PCL or PEO-PBCL block copolymer micelles were prepared through

formation of mixed micelles by a co-solvent evaporation method as described previously [8,22].
Briefly, either PEO-PCL (18 mg) and PEO-PCL-PCC-Cy5.5 (2 mg) or PEO-PBCL (18.88 mg)
and PEO-PBCL-PCC-Cy5.5 (1.12 mg) were mixed and dissolved in THF (0.4 mL). The solution
was added to 4 mL of doubly distilled water in a drop-wise manner under moderate stirring at
room temperature, followed by evaporation of THF under vacuum. The prepared micellar

8
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solution was then centrifuged to remove any aggregates. The concentration of Cy5.5 dye in the
micelles was 0.4 µg/mg of the polymer.
Cy5.5-loaded PEO-PCL or PEO-PBCL block copolymer micelles with P18-4 peptide

RI
PT

modification on their surface were prepared by co-solvent evaporation method as described
above. For peptide density of 0.1 mol/mol of the polymer, mixed micelles were prepared using
either PEO-PCL (9.0 mg), P18-4-PEO-PCL (9.0 mg), and PEO-PCL-PCC-Cy5.5 (2.0 mg); or

SC

PEO-PBCL (9.4 mg), P18-4-PEO-PBCL (9.4 mg), and PEO-PBCL-PCC-Cy5.5 (1.1 mg). For
peptide density of 0.2 mol/mol of the polymer, mixed micelles were prepared using either P18-4-

M
AN
U

PEO-PCL (18.0 mg), and PEO-PCL-PCC-Cy5.5 (2.0 mg); or P18-4-PEO-PBCL (18.9 mg), and
PEO-PBCL-PCC-Cy5.5 (1.1 mg). Polymeric micelles with low peptide density of 0.1 mol/mol of
the polymer were termed as 10%P18-4-PEO-PCL or 10%P18-4-PEO-PBCL. Polymeric micelles
having high peptide density of 0.2 mol/mol of the polymer, termed as 20%P18-4-PEO-PCL or

µg/mg of the polymer.

TE
D

20%P18-4-PEO-PBCL. The concentration of Cy5.5 dye in the P18-4 decorated micelles was 0.4

The Z-average size and size distribution of micelles were measured by dynamic light

EP

scattering (DLS) using a commercial Zetasizer Nano-ZS (Malvern Instruments, Worcestershire,
UK). All DLS measurements were made at 25.0 ± 0.1 °C with a 173° scattering angle. The

AC
C

samples were dissolved with deionized water and centrifuged prior to analysis. For this
measurement, plain PEO-PCL-PCC or PEO-PBCL-PCC were used in the preparation of
micelles, instead of PEO-PCL-PCC-Cy5.5 or PEO-PBCL-PCC-Cy5.5, respectively. This is
because the excitation and emission spectra of Cy5.5 would interfere with the He-Ne 633 nm
laser of the Zetasizer Nano-ZS.

9
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The CMC of the polymeric micelles was determined using fluorescence spectroscopy.
Briefly, solutions of Cy5.5-loaded unmodified or P18-4 decorated PEO-PCL or PEO-PBCL
micelles having concentrations ranging from 400-0.2 µg/mL were prepared in 96-well opaque

RI
PT

plates. The intensity of light emitted at 707 nm after excitation at 673 nm was measured by
fluorescence spectroscopy at 25 °C using a fluorescence spectrophotometer.

Kinetic stability of the micellar formulations was evaluated after incubation with a

SC

destabilizing agent, sodium dodecyl sulfate (SDS) according to previously published method
[23,29]. Briefly, micellar stock solutions of PEO-PCL, PEO-PBCL, 10%P18-4-PEO-PCL, or

M
AN
U

10%P18-4-PEO-PBCL having concentrations of 3 mg/mL were mixed with aqueous stock
solution of SDS (20 mg/mL) at a ratio of 2:1 v/v (micelle:SDS). Samples were analyzed at
predetermined time intervals by DLS for intensity distribution as well as polydispersity index

TE
D

(PDI).

2.7. In vitro cell uptake study using flow cytometry
MDA-MB-231-luc cells or MCF10A cells were seeded into 24-well plates at densities of

EP

1 × 105 cells/well and incubated at 37 °C for 24 h until they are 70% confluent. Free Cy5.5 and
micelles of PEO-PCL, PEO-PBCL, 10%P18-4-PEO-PCL, 10%P18-4-PEO-PBCL, 20%P18-4-

AC
C

PEO-PCL, 20%P18-4-PEO-PBCL at a concentration of 0.2 µg/mL of Cy5.5 (equivalent to 0.5
mg/mL of micellar solution) were added to the wells in triplicate and incubated with cells for 4
and 24 h at 37 °C. For the competition experiments, MDA-MB-231-luc cells were pre-incubated
with excess free p18-4 peptide (1 mg/mL) for 30 min and then incubated with the above
mentioned formulations for 24 h at 37 °C according to a previously described method [30]. After
the incubation period, cells were washed three times with cold PBS and trypsinized. A 4%

10
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paraformaldehyde in PBS solution was added to fix the cells and the Cy5.5 uptake was acquired
on a BD FACSCalibur™ flow cytometer (BD Biosciences, Franklin Lakes, NJ). The cellassociated Cy5.5 was excited using a red-diode laser (635 nm) and the FL4 channel (675 nm)

2.8. In vitro cell uptake study using confocal microscopy

SC

software (De Novo Software, Los Angeles, CA).

RI
PT

was used to detect the cell-associated fluorescence. The data was analyzed with FCS Express™

Confocal microscopy was used to assess the uptake of conjugated Cy5.5 in different

M
AN
U

micellar formulations in MDA-MB-231-luc cells. Cells were seeded into 12-well plates
containing round cover slips (0.2 mm thickness) at densities of 2 × 104 cells/well and incubated
at 37 °C for 24 h until they are 20% confluent. Free Cy5.5 and micelles of PEO-PCL, PEOPBCL, 10%P18-4-PEO-PCL, 10%P18-4-PEO-PBCL, 20%P18-4-PEO-PCL, and 20%P18-4-

TE
D

PEO-PBCL at a concentration of 0.2 µg/mL of Cy5.5 (equivalent to 0.5 mg/mL of micellar
solution) were added to the wells in triplicate and incubated with cells 24 h at 37 °C. After the
incubation period, cells were washed three times with cold PBS and fixed for 10 m using 4%

EP

paraformaldehyde in PBS solution. The cover-slips were removed and were inverted on a slide
with a drop of mounting media containing DAPI. The slides were allowed to cure in the dark for

AC
C

24 h. Uptake of Cy5.5 in cells was visualized by a Zeiss LSM 710 confocal microscope (Carl
Zeiss Microscope systems, Jena, Germany) using blue (Ex: 405 nm; Em: 410-500 nm) and red
(Ex: 633 nm; Em: 633-744 nm) filters with 20× magnification. The images were analyzed using
Zen 2012 software (Carl Zeiss Microscope systems, Jena, Germany).

2.9. Animal model
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Female athymic NIH-III mice were purchased from Charles River (Wilmington, MA).
All experiments were performed using 4-6 week old female mice. All animal studies were
conducted in accordance with the guidelines of the Canadian Council on Animal Care (CCAC)

RI
PT

with approval from the Animal Care and Use Committee (ACUC) of the University of Alberta
(Edmonton, AB, Canada). Mice were kept on the 2014S Teklad Global 14% protein rodent
maintenance diet which is low on chlorophyll to minimize fluorescence from food. To establish

SC

the orthotopic mammary fat pad tumor model, mice were randomly assigned into five groups of
six mice per group. Mice were injected with 2 × 106 MDA-MB-231-luc cells in 50 µL solution

M
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of 50% Matrigel Basement Membrane Matrix (BD Biosciences, Franklin Lakes, NJ), into the left
abdominal mammary fat pad [31]. The mice were used when the tumors reached a size of 600
mm3 (4 weeks after injection). Animals were monitored daily according to previously reported

TE
D

method [30].

2.10. In vivo imaging and tissue biodistribution

Animals were treated with micellar solutions of Cy5.5-loaded PEO-PCL, PEO-PBCL,

EP

10%P18-4-PEO-PCL, and 10%P18-4-PEO-PBCL at concentrations of 250 mg/kg of body
weight (equivalent to 0.1 mg/kg of free Cy5.5) [32] by IV injection through the tail vein. At

AC
C

various time-points of 4, 24, 48, and 72 h, mice were imaged for fluorescence and
bioluminescence using the IVIS Spectrum Preclinical In Vivo Imaging System (PerkinElmer,
Waltham, MA). For in vivo fluorescence imaging, animals were imaged for 0.5 s, 10 bin, level B
at an excitation and emission wavelength of 680 nm and 720 nm respectively. Spectral unmixing
was used to analyze the images and remove traces of autofluorescence. For bioluminescence

12
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imaging, luciferin potassium salt (150 mg/kg) in DPBS was injected sc into the loose skin on the
back of the neck 15 m prior to imaging. Animals were imaged for 0.5 s, 10 bin, level B.
At 48 and 72 h time-points, three mice were randomly selected from each group and

RI
PT

euthanized immediately after in vivo bioluminescence imaging. Tumors and other organs (liver,
lung, kidneys, heart, spleen, and brain) were excised and soaked in a 12-well plate containing
luciferin (300 µg/mL) prior to imaging. The organs were imaged for fluorescence and

SC

bioluminescence using the IVIS Spectrum Imaging System. For ex vivo fluorescence imaging,
animals were imaged for 0.5 s, 10 bin, level B at an excitation and emission wavelength of 680

M
AN
U

nm and 720 nm respectively. For bioluminescence imaging, animals were imaged for 0.5 s, 10
bin, level B.

2.11. Statistics

TE
D

Compiled data were presented as means ± standard deviation (SD) or mean ± standard
error (SE). Where feasible, the data were analyzed for statistical significance using unpaired
student’s t-test, or one-way analysis of variance (ANOVA) followed by Tukey's post-hoc test as

AC
C

3. Results

EP

noted in the results section. The level of significance was set at α ≤ 0.05.

3.1. Characteristics of NIR dye labeled PEO-PCL and PEO-PBCL block copolymers
Labeling of PEO-PCL and PEO-PBCL block copolymers with NIR dye was

accomplished in three steps (Scheme 1): first, PEO-PCL and PEO-PBCL were synthesized by
ring-opening polymerization of ε-caprolactone and α-benzyl carboxylate-ε-caprolactone
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monomer, respectively, in the presence of methoxy PEO [22]. The molecular weights of PEOPCL and PEO-PBCL were measured to be 6290 and 7700 g/mol, respectively, by 1H NMR (Fig.
S2, Supporting Information). The degree of polymerization (DP) of the core-forming block was

RI
PT

calculated to be 11 for both PEO-PCL and PEO-PBCL (Table S1, Supporting Information). In
the second step, α-propargyl carboxylate-ε-caprolactone (PCC) was conjugated to the PEO-PCL
and PEO-PBCL end. Conjugation of PCC to PEO-PCL or PEO-PBCL led to a decrease in DP of

SC

PCL and PBCL segments in the block copolymers from 11 to 7. Finally, Cy5.5 azide was
conjugated to the PCC end of PEO-PCL-PCC or PEO-PBCL-PCC via copper-catalyzed azide-
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alkyne cyclo-addition (CuAAC) click chemistry reaction [33]. The average molar conjugation
efficiency of Cy5.5 to the block copolymers was 56.9 % and 76.1 % for PEO-PCL-PCC-Cy5.5
and PEO-PBCL-PCC-Cy5.5, respectively. PEO-PBCL-PCC showed significantly higher
conjugation efficiency of Cy5.5 than PEO-PCL-PCC (P < 0.05; student's t-test). P18-4 was

TE
D

successfully conjugated to the PEO end of acetal-PEO-PCL or acetal-PEO-PBCL with an
average molar conjugation of 20.1 % and 20.5 %, respectively, as confirmed by HPLC (Table

EP

S1, Scheme S3, Supporting Information) [5,34].

3.2. Characteristics of mixed polymeric micelles without and with NIR labeling
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Cy5.5 labeled block copolymers were assembled to polymeric micelles by a co-solvent

evaporation method through preparation of mixed micelles (Scheme 2) [8,22]. Mixed micelles at
smilar conditions and ratios without Cy5.5 were also developed to make micelles compatiable
with DLS measurements. The physicochemical characteristics of prepared mixed polymeric
micelles without Cy5.5 are listed in Table 1. The average size of mixed micelles formed from
PCL containing block copolymers was significantly higher (P < 0.05; Students' t-test) compared
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to micelles formed from PBCL containing block copolymers. Similar results were seen in the
case of PDI. The average size of PEO-PBCL micelles showed a significant increase (P < 0.05;
one-way ANOVA) as the P18-4 peptide was attached and its density was increased. The

RI
PT

increasing trend in average diameter was only observed for mixed micelles of PEO-PCL at 20 %
P18-4.

For NIR labeled mixed micelles, as the block copolymer forms micelles, the Cy5.5 dye

SC

enters the core thus showing a decrease in the intensity of emitted light (quenching). The
concentration at which the slope of the graph of emission v/s concentration starts to decrease is
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termed as the critical micellar concentration (CMC). Micelles formed from PBCL containing
block copolymers exhibited a 7-fold decrease in CMC when compared with those formed from
PCL containing block copolymers (Table 1) similar to previous findings where a different
method was used to measure CMC of similar structures [23]. Formation of mixed micelles with
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P18-4 modified block copolymers did not significantly change the CMC of block copolymers (P
> 0.05; one-way ANOVA) irrespective of the P18-4 modified block copolymer density. Of note
is that at the highest concentration of 400 µg/mL of the copolymers, the intensity of emitted light

EP

from all micellar systems was similar to each other (P < 0.05; one-way ANOVA, Tukey's posthoc test) indicating that all the micellar systems had a similar quenching of the Cy5.5 dye.

AC
C

PEO-PCL based micelles, unmodified or modified with 10 mol % P18-4 peptide showed

a significant decrease in the signal intensity of the micellar peak to ~50 and ~21 %, respectively,
within 24 h of incubation with SDS (Fig. 1). PEO-PBCL based micelles, on the other hand,
whether modified with P18-4 or not, showed a signal intensity of ≥ 90 % throughout the 72 h
incubation with SDS. Hence, attachment of benzyl carboxylate to the micellar core resulted in
improved stability against micellar dissociation in the presence of SDS. This was in line with
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previously published results from our lab [23]. Formation of mixed micelles with P18-4 modified
PEO-PCL or PEO-PBCL, however, led to a decrease in the stability of the micelles against
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dissociation.
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Scheme 1. Synthetic scheme for the preparation of Cy5.5-labeled polymeric micelles.
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Scheme 2. Combination of block copolymer for preparing the Cy5.5 labeled mixed micelles.
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Table 1. Characteristics of prepared mixed block copolymer micelles.
P18-4 density
(mol/mol)b

Z-Average micellar
size ± SD (nm)c

PDI ± SDd

CMC ± SD (µM)e

PEO-PCL (I:II)

-

148.5 ± 13.6

0.499 ± 0.051

3.40 ± 0.28

PEO-PBCL (IV:V)

-

30.2 ± 0.4 *

0.184 ± 0.009*

0.49 ± 0.07*

10%P18-4-PEO-PCL (I:II:III)

0.1

110.0 ± 11.8

0.831 ± 0.158

3.71 ± 0.39

10%P18-4-PEO-PBCL (IV:V:VI)

0.1

40.4 ± 0.4 *

0.302 ± 0.019*

0.77 ± 0.02*

20%P18-4-PEO-PCL (I:II:III)

0.2

318.4 ± 89.7

0.422 ± 0.063

4.22 ± 0.73

20%P18-4-PEO-PBCL (IV:V:VI)

0.2

52.2 ± 0.8 *

0.293 ± 0.022*

1.18 ± 0.40*

a

RI
PT

Polymeric
Micelles a
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The number shown in the parentheses indicates the combination of block copolymers used in mixed micelles (see
Scheme 2).
b
Density of peptide in polymeric micelles expressed as the mole of peptide per mole of polymer.
c
Z-Average micellar size estimated by DLS technique (n = 3).
d
Average polydispersity index (PDI) of micellar size distribution (n = 3).
e
Measured from the onset of a decrease in the slope of the intensity of emission of Cy5.5 as a function of block copolymer
concentration (n = 3).
*
Significantly different from its counterpart micelle containing PCL (P < 0.05; Student's t-test).

Fig. 1. Characteristics of prepared mixed micelles. The percentage intensity of micellar peak (2 mg/mL) as a
function of time in the presence of SDS (6.7 mg/mL). Each point represents mean ± SD (n = 3).
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3.3. In vitro uptake by breast cancer versus normal cells
As seen in Fig. 2, the fluorescent signal for peptide-modified PEO-PCL and PEO-PBCL
micelles in MDA-MB-231-luc breast cancer cells was higher than that for plain micelles

RI
PT

particularly after 24 h incubation (P < 0.05; Students' t-test). At this incubation time, PEO-PCL
and PEO-PBCL micelles presenting 10 mol % of P18-4 peptide demonstrated 1.7- and 1.3-fold
greater breast cancer cell associated fluorescence (Fig. 2A) than unmodified micelles,

SC

respectively. In the case of PEO-PCL and PEO-PBCL micelles presenting 20 mol % of P18-4
peptide, cellular association increased by 2.0- and 1.2-fold, when compared to unmodified
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micelles, respectively. The unmodified PEO-PCL and PEO-PBCL micelles showed similar cell
associated fluorescence (P > 0.05; Students' t-test) at 4 h. However, PEO-PCL micelles exhibited
a significantly higher cell associated fluorescence than PEO-PBCL ones at 24 h (P < 0.05;
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unpaired students' t-test).
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Fig. 2. Cellular association of Cy5.5-labeled micelles by MDA-MB-231-luc (A), and MCF10A (B) cells. The bar
graphs show the mean fluorescence intensity (MFI) of the cells after 4 and 24 h incubation. This experiment was
also done with and without competition (pre-treatment using excess of free P18-4) using MDA-MB-231-luc cells
after 24 h incubation (C). The data are presented as mean ± SE (n=3). *: Significant difference between PEO-PCL
and PEO-PBCL (with or without peptide on their surface). #: Significant difference between PEO-PCL and P18-4PEO-PCL, or PEO-PBCL and P18-4-PEO-PBCL. §: Significant difference from the competition group after preincubation with excess free peptide (P < 0.05; unpaired Students' t-test).
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The uptake of Cy5.5-loaded polymeric micelles was also determined in MCF10A
mammary epithelial cells as seen in Fig. 2B. In the case of MCF10A cells, after 24 h incubation,
PEO-PCL and PEO-PBCL micelles presenting 10 mol % of P18-4 peptide demonstrated 1.4- and
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1.1-fold greater cellular association than unmodified micelles, respectively. This was lower than
the cellular association seen by these micelles in MDA-MB-231-luc breast cancer cells.
However, in the case of PEO-PCL and PEO-PBCL micelles presenting 20 mol % of P18-4
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peptide, MCF10A cellular association increased by 2.9-fold and 1.6-fold, respectively, which
was more than 2.0-fold and 1.2-fold, seen in the breast cancer cells (Fig. 2A). This indicated a
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higher non-specific cellular association for PEO-PCL and PEO-PBCL micelles modified with 20
mol % of P18-4 peptide.

To explore whether the increased cell association in MDA-MB-231-luc cells is due to the
presence of receptor for the P18-4 peptide, competition study was carried out, in which cells

TE
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were pre-treated with excess P18-4 peptide before incubating the cells for 24 h with PCL and
PBCL based micellar formulations. As seen in Fig. 2C, the presence of excess free P18-4 peptide
significantly reduced the cellular association of PEO-PCL and PEO-PBCL micelles presenting

EP

10 mol % of P18-4 peptide (P < 0.05; unpaired students' t-test). However, the presence of excess
free P18-4 peptide did not affect the cellular association of PEO-PCL micelles presenting 20
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mol % of P18-4 peptides. For PEO-PBCL micelles at this level of peptide conjugation, still
competition with free peptide was observed.
The uptake of Cy5.5-labeled polymeric micelles was determined by MDA-MB-231-luc

breast cancer cells using confocal microscopy after 24 h incubation. As seen in Fig. 3, peptide
modification increased intracellular fluorescence of labeled PEO-PCL and PEO-PBCL micelles
in the cytoplasm. Both PEO-PCL and PEO-PBCL micelles presenting 20 mol % of P18-4
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peptide, showed strong fluorescence in cells when compared with their unmodified counterparts
or counterparts presenting 10 mol % of P18-4 peptide. Also, PEO-PCL micelles, with or without
P18-4 modification showed stronger Cy5.5 fluorescence in cells when compared to PEO-PBCL
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micelles. These observations were in accordance with our past findings and data from cellular
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association studies (Fig. 2).
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Fig. 3. Cellular uptake of Cy5.5-labeled micelles with different polymer compositions: PEO-PCL (A), 10%P18-4PEO-PCL (B), 20%P18-4-PEO-PCL (C), PEO-PBCL (D), 10%P18-4-PEO-PBCL (E), 20%P18-4-PEO-PBCL (F),
and free Cy5.5 (G), in MDA-MB-231-luc cells using confocal microscopy after 24 h incubation. Images represent
nuclear stain DAPI (pink) alone, Cy5.5 (blue-yellow) alone, and the merged dyes.
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3.4. Imaging of Cy5.5 labeled micelles in orthotopic breast cancer mouse model
The bioluminescence signal can be seen at the sight of injection (Fig. 4F) i.e. left
mammary fat pad, indicating successful generation of primary breast tumor at its natural

RI
PT

location. The imaging studies (Fig. 4) showed, upon intravenous injection, plain PEO-PCL
micelles, started accumulating in the liver, tumor, and neck (presumably the cervical lymph
nodes) within 4 h post-injection. After 24 h, these micelles started showing higher accumulation

SC

in tumor along with increased accumulation in liver and neck. Dorsal images showed uptake of
plain PEO-PCL micelles in the kidneys and spleen. Peptide modified PEO-PCL micelles had
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similar patterns of distribution except that they only showed uptake in kidneys upon dorsal
assessment and no accumulation in spleen. Similar results were seen for the ventral images after
48 h, with decrease in fluorescence in both liver and tumors 72 h post-injection. Dorsal images
presented increased fluorescence in kidneys for both PEO-PCL micelles at 48 h and 72 h, which

TE
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perhaps points to the elimination of PEO-PCL polymers from this organ at later time points.
In the case of PEO-PBCL micelles, unmodified micelles accumulated primarily in the
tumor with strong fluorescence signals throughout the body whereas PEO-PBCL micelles

EP

modified with 10 mol % P18-4 peptide showed uptake primarily in the tumor with weak
fluorescent signals throughout the body, 4 h post-injection. After 24 h post-injection, ventral
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images showed unmodified PEO-PBCL micelles primarily in the tumor with weaker
fluorescence signals throughout the body. In the case of PEO-PBCL micelles modified with P184 peptide, fluorescent signals were primarily at the tumor site. Ventral images at 48 and 72 h for
both, unmodified and 10 mol % P18-4 peptide modified PEO-PBCL micelles, showed similar
results of strong fluorescent signals primarily from the tumor site. Dorsal images at 24, 48, and
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72 h time-points showed strong fluorescent signals from the tumor site at exact locations that are
seen in the dorsal images of bioluminescence (Fig. S5, Supporting Information).
Comparing the average radiant efficiency in the tumor from the in vivo images, revealed
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P18-4 modified micelles to exhibit higher accumulation in the tumor at the earlier time-points. In
the case of PEO-PCL micelles, P18-4 modified micelles had a significantly higher accumulation
in the tumor site 4 h after injection when compared to their unmodified counterparts (P < 0.05;

SC

Student's t-test). At later time-points, the average radiant efficiency significantly decreased and
was similar for both plain and P18-4 modified PEO-PCL micelles. This decrease in the
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fluorescent intensity may be due to clearance by the kidneys and liver as seen in Fig. 4.
In the case of PEO-PBCL micelles, P18-4 modified micelles presented a significantly
higher accumulation in the tumor site 4 and 24 h after injection when compared to their
unmodified counterparts (P < 0.05; Student's t-test). For P18-4 modified PEO-PBCL micelles,
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the average radiant efficiency in the tumor reached maximum at 24 and 48 h post-injection after
which it started to decrease by 72 h. In the case of plain PEO-PBCL micelles, the average radiant
efficiency shows an increasing trend from 4 - 72 h reaching a value similar to the maximum
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average radiant efficiency of P18-4 modified PEO-PBCL micelles, only after 72 h.
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Fig. 4. In vivo NIR imaging of Cy5.5-labeled micelles composed of different polymers: PEO-PCL (A), 10%P18-4-

AC
C

PEO-PCL (B), PEO-PBCL (C), and 10%P18-4-PEO-PBCL (D), and untreated (E) at 4, 24, 48, and 72 h after
intravenous administration. Images show mice in the ventral position. Each time-point represents image of one
representative mouse from a group of six mice. Images in (F) show the bioluminescence signals from MDA-MB231-luc cells. Each time-point represents image of one representative mouse in the groups. The bar graphs represent
the average radiant efficiency in tumor of plain and P18-4 modified PEO-PCL (G), and PEO-PBCL (H) micelles at
4, 24, 48, and 72 h after intravenous administration. *Significantly different from its plain counterpart (P < 0.05,
unpaired Students' t-test).
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Fluorescence from Cy5.5 was used to image the biodistribution of PEO-PCL and PEOPBCL micelles ex vivo in different organs from animals euthanized at 48 and 72h after micellar
tail vein injection. As seen in Fig. 5B, both plain and P18-4 peptide modified PEO-PCL
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micelles, showed increased fluorescence primarily in the kidneys indicating clearance through
kidneys within 72 h. This was similar to the results seen during in vivo imaging (Fig. 4B). Both
plain and peptide modified PEO-PBCL micelles, on the other hand, showed increased
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fluorescence signals in the liver and tumors. The average radiant efficiency of the tumor was
significantly higher for plain and P18-4 modified PEO-PBCL micelles when compared with their

M
AN
U

PEO-PCL micelle counterparts (P < 0.05; one-way ANOVA). P18-4 modification; however, did
not significantly increase the average radiant efficiency of the tumor at both 48 and 72 h when
compared to plain PEO-PCL and PEO-PBCL micelles. This was similar to the results of 48 and
72 h readings in in vivo images (Fig. 4C). PEO-PBCL micelles, whether unmodified or modified
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with P18-4 peptide, showed a significantly higher average radiant efficiency in heart, liver, lung,
and spleen, and a significantly lower average radiant efficiency in kidney when compared with
their PEO-PCL counterparts at 48 h time-point (P < 0.05; one-way ANOVA). The higher

EP

average radiant efficiency in the kidneys indicated faster clearance for PEO-PCL micelles.
Similar results were also seen after 72 h, but were not statistically significant for some groups.
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P18-4 modification did not significantly change the average radiant efficiency in most organs
other than the tumor when compared to plain micelles (P > 0.05; one-way ANOVA) except for
spleen and heart. P18-4 modified PEO-PBCL micelles had a reduced radiant efficiency at 48 and
72 h in spleen and P18-4 modified PEO-PCL micelles had a reduced radiant efficiency at 48 h in
heart when compared to their unmodified counterpart. Although the average radiant efficiency
can be used to compare the distribution in any organ amongst different groups, it is not advisable
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to use this measure to compare the distribution of NIR label between different organs. This is
because of the attenuation effect of hemoglobin on NIR emission and presence of hemoglobin at
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different quantities in different organs [35].
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Fig. 5. Ex vivo NIR imaging of Cy5.5-labeled micelles composed of different polymers: PEO-PCL (A), 10%P18-4PEO-PCL (B), PEO-PBCL (C), and 10%P18-4-PEO-PBCL (D), untreated (E), and bioluminescence signal (F) at 48
and 72 h after intravenous administration. Images show (counter clockwise from top left corner) liver, kidneys,
lungs, spleen, brain, tumor, and heart. Each time-point represents image of one mouse from the group. The graphs at
the bottom (G) represent the average radiant efficiency of cy5.5 fluorescence in tumor, liver, kidneys, spleen, heart,
and lungs at 48 and 72 h after intravenous administration. *Significant difference between PEO-PCL and PEOPBCL (with or without peptide on their surface). #Significant difference between PEO-PCL and P18-4-PEO-PCL,
or PEO-PBCL and P18-4-PEO-PBCL (P < 0.05; unpaired Students' t-test).
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4. Discussion

The main objective of our study was to develop traceable polymeric micellar carriers that
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can be used to investigate the effect of modifications in the micellar core and shell structure on
their in vivo biodistribution. For this purpose, we have chemically conjugated the near infra-red
(NIR) probe Cy5.5, to the hydrophobic block of PEO-PCL and PEO-PBCL. The surface of both

SC

nanocarriers were also modified with a novel breast cancer targeting peptide ligand developed by
our research group in previous studies [25]. The effect of core/ and shell modifications on the
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micellar physicochemical properties, in vitro cancer cell specificity, and in vivo biodistribution in
mice bearing orthotopic MDA-MB-231 breast tumors was then assessed.
NIR dyes are suitable for optical imaging in live animals enabling deeper tissue imaging
[5,6]. In polymeric micelles, the NIR probes can either be conjugated to the hydrophilic shell of
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the micellar system [21], or encapsulated [36] or conjugated [5,37] to the hydrophobic core
[7,38]. Conjugation of NIR probes to the micellar surface can change the interaction of the
nanocarrier with proteins from the complement system, thus leading to their early removal

EP

through reticuloendothelial system recognition. It can also affect the interaction of nanocarriers
with other non-specific normal cells upon encounter. Physical encapsulation of NIR probes into
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the core of micelles on the other hand, cannot guarantee the detainment of the NIR probe within
the carrier under sink in vivo condition. To the best of our knowledge, this is the first report on
the development of traceable PEO-PCL and PEO-PBCL micelles through chemical conjugation
of NIR dye to the poly(ester) core of these nanocarriers and their tumor targeting ligand modified
counterparts. Conjugation of NIR dyes to the poly(ester) structures is particularly challenging
due to the unstable nature of the poly(ester) bonds under the required harsh chemical reaction
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conditions. In this study, cy5.5 was selected as the NIR dye because it is widely used in
literature for tracking of nanocarriers and is available with various functional groups that enable
multiple types of chemical conjugations. However, from a clinical perspective, other FDA
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approved dyes such as indocyanine green might be preferable due to its excitation and emission
>780 nm at which wavelength there is no interference due to tissue autofluorescence, and
heamoglobin.
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The experiments were conducted using PEO-PCL and PEO-PBCL micelles with similar
DP (8-11) for the ε-caprolactone and α-benzyl carboxylate-ε-caprolactone monomers and the
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PEO (~ 5,000 Da) was used as the macro-initiator for their polymerization. The DP values were
chosen to be uniform for the core-forming block in both polymers to eliminate the possibility of
differences in our observations due to the hydrophobic block length. The Cy5.5 labeled PEOPCL and PEO-PBCL polymers were then mixed with either plain or P18-4 modified PEO-PCL
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or PEO-PBCL polymers, respectively, to achieve NIR labeled micelles (Scheme 1). Mixed PEOPCL micelles showed a significantly larger average size (≥100 nm) and PDI compared to their
PEO-PBCL counterparts (~ 50 nm) (Table 1, Fig. S4, Supporting Information). The decrease in
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the size of PEO-PBCL micelles when compared to PEO-PCL micelles may be due to the ability
of PEO-PBCL to form π-π stacking interactions which may enable better packing of the micelles.
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The decrease in PDI of PEO-PBCL micelles is also an indication of the improved
physicochemical stability of these micelles comapred to PEO-PCL micelles [23].
In line with our previous findings [23], we have seen a higher thermodynamic stability

for PEO-PBCL based micelles compared to PEO-PCL ones as evidenced by lower CMC of
PEO-PBCL micelles at similar length of the block copolymers (Table 1). The high
thermodynamic stability of the polymeric micelles is an important factor determining the
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stability of polymeric micelles in the biological system [39]. Presence of aromatic groups on the
PCL block also led to an increase in the kinetic stability as measured by a decrease in the rate of
dissociation of micelles when incubated with SDS (Fig. 1). This may be due to the π-π stacking

RI
PT

of the benzyl carboxylate groups in PEO-PBCL micelles leading to resistance towards
dissociation [23].

P18-4 is a stable decapeptide having the amino acid sequence WxEAAYQrFL (lower
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case letter denotes ᴅ-amino acid; X is norleucine) and a molecular weight of 1296 Da. The
peptide is shown to have a high affinity for breast cancer cells compared to noncancerous cells.
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This peptide is believed to interact with Keratin-1 on breast cancer cells [40]. Formation of
mixed micelles with P18-4 modified polymers did not affect the thermodynamic stability of
micelles, but decreased their kinetic stability in the presence of SDS. Pre-treatment of cells with
free P18-4 peptide, resulted in a reduction in the uptake P18-4 modified micelles in MDA-MB-
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231 breast cancer cells to the level seen for the unmodified micelles (Fig. 2C). This indicates that
the P18-4 modified polymeric micelles are taken up through receptor mediated endocytosis
[25,41]. Increasing the P18-4 density significantly increased the cellular uptake of Cy5.5-loaded

EP

micelles in MDA-MB-231 cells (Fig. 2 and Fig. 3). These results are in agreement with those
reported by us for P18-4 modified liposomes and p160 modified micelles [30,42]. At higher
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peptide density of 20 mole %, presence of free P18-4 peptide did not affect the uptake of P18-4
modified PEO-PCL and PEO-PBCL micelles. Besides, our results have shown higher uptake of
micelles presenting high P18-4 density (20 mol %) by MCF10A normal cells which suggest the
possibility of non-specific cell uptake. Similar results were also seen previously for high density
P18-4 modified liposomes in MCF10A cells [30]. In contrast, micelles modified at 10 mol %
with P18-4 were more specifically associated with MDA-MB-231 compared to MCF10A cells.
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This is in line with previous reports which have shown the P18-4 peptide to have higher
specificity for cancer cells and at the same time be internalized by these cells [25].
Micelles formed from PEO-PCL showed significantly higher uptake in MDA-MB-231
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breast cancer cells compared to the ones composed of PEO-PBCL [43]. The lower
thermodynamic and kinetic stability of PEO-PCL micelles might have led to their dissociation
inside the cell, thus de-quenching the Cy5.5 dye, showing higher fluorescence when compared to

SC

PEO-PBCL micelles. In addition to MFI, an increase in the % Cy5.5 positive cells for PEO-PCL
micelles when compared to PEO-PBCL micelles has also been observed.
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In vivo biodistribution studies were carried out in an orthotopic breast tumor animal
model [44]. It is known that the response to drugs can be highly varied depending on the site of
the tumor. For instance, doxorubicin could inhibit 80% of the tumor growth in an in vivo
xenograft model, whereas only 40% drug activity was found in tumors at the orthotopic site [45].
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Thus, orthotopic models are necessary for a more accurate analysis of tumor growth and
treatment. To follow the growth of the tumor and also track any possible metastasis, MDA-MB231 cells expressing firefly luciferase were used.
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Both PEO-PCL and PEO-PBCL micelles showed fluorescence in liver, spleen, and
kidneys indicating their recognition by the major organs of RES along with renal clearance in

AC
C

kidney, respectively (Fig. 5). Plain and P18-4 modified PEO-PCL micelles presented higher
accumulation in kidneys indicating faster renal clearance compared to their PEO-PBCL
counterparts. Glomerular filtration, which is the first step in renal clearance, is highly sizeselective. The PEO-PCL micelles had a size of ≥ 100 nm which is higher than the threshold for
renal clearance [46]. It is; therefore, most likely that the PEO-PCL micelles dissociated in the
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serum leading to their faster clearance. In line with this assumption, PEO-PCL micelles have
shown lower in vitro thermodynamic and kinetic stability compared to PEO-PBCL micelles [43].
PEO-PBCL micelles were shown to be more stable than PEO-PCL ones and accordingly
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presented higher tumor accumulation than the PEO-PCL ones. However, in addition to the
tumor, PEO-PBCL micelles had significantly higher accumulation in heart, liver, lungs, and
spleen, but lower accumulation in the kidneys, when compared to PEO-PCL micelles (Fig. 5).
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The higher accumulation into the other organs may simply be a reflection of less elimination of
PEO-PBCL micelles through the kidneys and their higher retention in the blood compared to
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PEO-PCL micelles.

The micelles may further be developed for encapsulation of anti-cancer drugs and used as
theranostics for the simultaneous delivery of drug to tumor site and following the progress of
disease, at the same time. The thermodynamic and kinetic stability of the nanocarrier, however,
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may be influenced by the encap9sulated drug. This may impact the extent and kinetics of
micellar distribution in different organs, as well.

P18-4 modification resulted in more rapid accumulation of micelles in the tumor site. At
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later time points (> 4 h for P18-4 modified PEO-PCL and > 24 h for P18-4 modified PEO-PCL)
no significant difference in tumor accumulation of P18-4 modified mixed micelles versus plain
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micelles was noted, however. Previous studies using RGD modified nanocarriers has reported
similar results, although the receptor for RGD peptide is also over-expressed in the tumor
endothelium and the rapid accumulation for the RGD modified carriers may be due to the uptake
of these targeted nanocarriers in the tumor endothelium rather than due to retention in the tumor
cells [47]. Unlike RGD peptide, the receptor for P18-4 is shown to be majorly expressed by
tumor cells rather than angiogenic endothelium increasing the chance of retention by tumor cells
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for P18-4 modified micelles. The longer effect of peptide in tumor accumulation of PEO-PBCL
may also be a reflection of higher stability and slower dissociation and separation of peptide
conjugated polymers from these nano-carriers.
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Interestingly, P18-4 modified PEO-PBCL micelles showed lower accumulation in the
spleen, while P18-4 modified PEO-PCL micelles showed lower accumulation in heart at 48h
when compared to the corresponding

micellar constructions without the peptide. Previous
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studies have demonstrated that high densities of peptides on the nanocarrier surface can lead to
an abnormal uptake by the RES organs like spleen and liver resulting in faster clearance from the

M
AN
U

body [48,49]. Therefore the 10 mole % density of P18-4 micelles may be considered appropriate.

5. Conclusion
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In general, lableing of PEO-poly(ester) micelles through chemical conjugation of NIR
probe Cy5.5 to their poly(ester) core, provided means for following the fate of PEO-poly(ester)
micelles both in vitro and in live animals facilitating discovery of structure activity relationships

EP

with respect to the biodistribution and targeting capabilities of these nano-carries. In this study,
the highly stable PEO-PBCL micelles showed exteded residence time and higher levels at breast

AC
C

tumor follwoing intravenous administartion in tumor bearing mice, perhaps due to theattenuated
dissociation and renal elimination of PEO-PBCL over PEO-PCL micelles. PEO-PBCL micelles,
however, showed higher distribution to RES organs. Surface modification of both nanocarriers
with the novel P18-4 peptide resulted in their higher and more specific uptake by breast cancer
cells in vitro and rapid accumulation at the tumor site, in vivo.
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The results of this study demonstrated the tremendous potential of developed traceable
nanocarriers, and their P18-4 modified counterparts for further advancement to image-able
targeted therapy tools for breast cancer. The results also shed light on the structural

SC

distribution for PEO-PCL based micelles.

RI
PT

characteristics of block copolymers that can be used to optimize the kinetics and extent of tumor
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